ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 1835 • ACR Convergence 2025

    Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis

    Alessandra Milone1, Giulio Forte2, Alessia Salzillo2, Barbara De Marino2, Rosa Giacca2, Francesco Ciccia3 and Daniele Mauro4, 1University of Campania L. Vanvitelli, Naples, 2University of Campania L. Vanvitelli, Naples, Italy, 3Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, 4University of Campania, Italy, Naples, Italy

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…
  • Abstract Number: 1744 • ACR Convergence 2025

    Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus

    Ekemini Ogbu1, Clare Treutel1, Angela Merritt2, Michael Wagner1 and Hermine Brunner1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Childrens Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) affects approximately 1 in 10,000 children in the United States, with the estimated prevalence of childhood neuropsychiatric SLE (NPSLE)…
  • Abstract Number: 1689 • ACR Convergence 2025

    Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support

    Kimberly Cabrera1, Priscilla Calvache2, Lillian Mendez3, Giselle Morales4 and Jillian Rose-Smith2, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, 3Patient Advocate, Carteret, NJ, 4Hospital for Special Surgery, Glendale, NY

    Background/Purpose: SLE is a life-threatening autoimmune disease that disproportionately affects African American (AA), Hispanic/Latino, & Asian populations. These communities experience serious health disparities, including more…
  • Abstract Number: 1547 • ACR Convergence 2025

    Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice

    Vanesa Calvo-Río1, Carmen Secada-Gómez1, Blanca Garcia-Magallon2, Deseada Palma-Sanchez3, Andrea García-Valle4, Irati Urionaguena Onaindia5, Adrián Mayo-Juanatey6, Paúl Hernández Velasco7, GUILLERMO GONZALEZ ARRIBAS8, Ana Pareja-Martínez9, Montserrat Corteguera10, Guillen Sada Urmeneta11, Paz Collado Ramos12, Jose Luis Tandaipan13, Juan Roberto Miguelez Sanchez14 and Ricardo Blanco1, 1Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 2Rheumatology. Hospital Universitario Puerta de Hierro, Madrid, Spain, 3Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, 4Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, 5Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, 6Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 7Nephrology, Hospital Universitario 12 de Octubre, Madrid. Spain, Madrid, Madrid, Spain, 8Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, 9Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, 10Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, 11Rheumatology. Hospital Reina Sofía, Tudela, Navarra, Spain, 12Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, 13Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, 14Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain

    Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…
  • Abstract Number: 1528 • ACR Convergence 2025

    Influence of Prednisone use over cardiovascular risk in patients with Systemic Lupus Erythematosus

    Esteban C. Garza-Gonzalez1, Fernanda M. Garcia-Garcia2, Oscar Azael Garza-Flores3, Rebeca L. Polina-Lugo4, Leslie Y. Lopez-Cantú2, Jose R Azpiri-Lopez5, Iris J. Colunga-Pedraza2, Jesus Alberto Cardenas-de la Garza6, Dionicio A. Galarza-Delgado2 and Diego Azamat Salcedo Almanza7, 1Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, 4Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 5Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 6Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 7Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disease associated with increased morbidity and mortality, particularly due to cardiovascular complications. Atherosclerotic cardiovascular disease…
  • Abstract Number: 1504 • ACR Convergence 2025

    High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants

    Richard Oppong1, Joanne Nititham2, Ashira Blazer3, Manuel Ugarte-Gil4, Jinoos Yazdany5, Maria Dall'Era6, Alexander Bick7, Lindsey Criswell2 and Cristina Lanata8, 1National Institutes of Health, Bethesda, MD, 2NIH/NHGRI, Bethesda, MD, 3University of Maryland Baltimore, Baltimore, Maryland, 4Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, 5UCSF, San Francisco, CA, 6Division of Rheumatology, University of California, San Francisco, CA, 7Vanderbilt University, Nashville, TN, 8NIH/NHGRI, Bethesda

    Background/Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by the presence of somatic mutations in hematopoietic stem cells that lead to the expansion of…
  • Abstract Number: 1487 • ACR Convergence 2025

    Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement

    Jennifer Rogers1, Amanda Eudy2, Connor Drake3, Tamara Somers4, David Pisetsky5, Christie Clipper6, Ralph Snyderman7, Anna Batsakes6, Leigh Saner6, Dana Burshell3, Mithu Maheswaranathan4, Lisa Criscione-Schreiber4, Rebecca Sadun8, Nathaniel Harris5, Kai Sun8, Kelsey Dunn6, Jenny Herndon6, Vonne Jacobs6 and Megan Clowse9, 1Duke, Durham, NC, 2Duke University, Raleigh, NC, 3Duke University School of Medicine, Durham, 4Duke University School of Medicine, Durham, NC, 5Duke University Medical Center, Durham, NC, 6Duke University, Durham, 7Duke Center for Personalized Health Care, Durham, NC, 8Duke University, Durham, NC, 9Duke University, Chapel Hill, NC

    Background/Purpose: To improve quality of life (QoL) in individuals with SLE, we developed the Whole Health Empowerment for Endotypes of Lupus (WHEEL) program—a 4-month, biweekly,…
  • Abstract Number: 1470 • ACR Convergence 2025

    Why Do Some Lupus Patients Skip Their Mycophenolate Mofetil? A Multi-Factorial Assessment of Patient Compliance

    Nidaa Bukhari1, Ali Rizvi1, Jian sun1, Zerai Manna2, Paul Schaughency3, Suraj Rajasimhan4 and Sarfaraz Hasni1, 1National Institutes of Health, BETHESDA, MD, 2NIH, Bethesda, MD, 3NIAID, NIH, Bethesda, MD, 4National Institutes of Health, Columbia, MD

    Background/Purpose: Nonadherence to medication is a significant confounder in assessing treatment efficacy for systemic lupus erythematosus (SLE), with rates reported up to 75% depending on…
  • Abstract Number: 1281 • ACR Convergence 2025

    Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus

    Alicia Tran1, Indrani Das2, Zhaoyu Ding3, Daniela Dominguez4, Sefi Kronenberg5, Lawrence Ng6, Alene Toulany1, Gwyneth Zai7, Deborah Levy1, Andrea Knight8 and Linda Hiraki1, 1The Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3SickKids Research Institute, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, Canada, 5Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, 6The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, 7Centre for Addiction & Mental Health, Toronto, ON, Canada, 8Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) face higher risks of depression and anxiety compared to healthy peers. In 2022, standardized mental health (MH)…
  • Abstract Number: 1087 • ACR Convergence 2025

    Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus

    Zoe Reed1, Catriona Wagner2, Xana Howard1, Alexandre Cammarata-Mouchtouris1, Study Team ALE06 Clinical1, Wade DeJager3 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Santa Cruz, CA, 3Oklahoma Medical Research Foundation, Oklahoma City

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with considerable clinical and molecular heterogeneity. Significant disparities exist in SLE, with minority populations experiencing…
  • Abstract Number: 0952 • ACR Convergence 2025

    Therapeutic Potential of PaPE-1 in Reducing TLR7-Mediated Inflammation in a Murine Model of Lupus

    Rachael Werner1, Jena Wirth1, Gary Gilkeson1 and Melissa Cunningham2, 1Medical University of South Carolina, Charleston, SC, 2Medical University of SC, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects women, underscoring the critical role of sex chromosomes and sex hormones—particularly estrogen—in…
  • Abstract Number: 0915 • ACR Convergence 2025

    A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models

    Yuhao Qin1, Huan Wang1, Han Gao1, Chongqi Zhang1, Chengpan Wang1, yanru fan1, wei ye1, yuan lin1, Lu Su2, Wenming Ren1 and cheng liao1, 1Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), 2Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China

    Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
  • Abstract Number: 0657 • ACR Convergence 2025

    Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE

    FNU Ruchi1, Ioana Coman1, Bryan Blaker1, Lucero Blaker1, Joy Park2, Jorge Cabezas1, Dilip Rao1, +Xiaojing Wang1, Aparna Godavarthy1, Marlene Marte Furment3, Sandy Nasr4, Sravani Lokineni5, Christina Donath4, SARA KAHLOWN6, Damira Sereda1, Binod Kc1, Ilya Ivyanskiy1, Bhavya Poudyal7, Arthur Weinstein8, Rosalind Ramsey-Goldman9, Michael Weisman10, Cynthia Aranow11, Mariko Ishimori10, Kyriakos Kirou12, Jihad Ben Gabr13, Sheetal Rayancha14, Nancy Olsen15, Fotios Koumpouras16, Judith Lin17, Stephen Faraone1, Daniel Wallace18, Michael McDermott19 and Andras Perl20, 1SUNY Upstate Medical University, Syracuse, NY, 2Upstate Medical University, Syracuse, NY, 3Medical Affiliates of Cape Cod, Hyannis, MA, 4SUNY Upstate University Hospital, Syracuse, NY, 5Deaconess Hospital, Evansville, IN, 6Suny upstate medical university, Camillus, NY, 7SUNY Upstate Medical University, Cicero, NY, 8retired from clinical practice, volunteer academic faculty, Claremont, CA, 9Northwestern University Feinberg School of Medicine, Chicago, IL, 10Cedars-Sinai Medical Center, LOS ANGELES, CA, 11Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, 12Hospital for Special Surgery, New York, NY, 13Division of Rheumatology & Clinical Immunology, SUNY Upstate Medical University, Syracuse, NY, 14SUNY Upstate Medical University, Jamesville, NY, 15Penn State University/Milton S Hershey, Hershey, PA, 16Yale School of Medicine, New Haven, CT, 17Ohio State University Wexner Medical Center, Columbus, OH, 18Cedars Sinai Medical Center, Studio City, CA, 19University of Rochester Medical Center, Rochester, NY, 20SUNY, Syracuse, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in 5 years. The major causes of death…
  • Abstract Number: 0634 • ACR Convergence 2025

    Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease

    Sarah Lieber1, Yongjay Kim2, Lucy Masto3, Amaya Smole4, Neha Nagpal1, Ranqing Lan1, Michael Parides1, Caroline Siegel1, Lisa Mandl1, Michael Lockshin5, Medha Barbhaiya1 and Lisa Sammaritano1, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Englewood Cliffs, NJ, 3Hospital for Special Surgery, San Francisco, CA, 4Hospital for Special Surgery, Brooklyn, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Although available evidence supports the benefits of lifestyle interventions in SLE, the prevalence of lifestyle and integrative health behaviors and their association with health-related…
  • Abstract Number: 0616 • ACR Convergence 2025

    Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study

    Juliana Silvatti1, Livia Almeida Dutra2, Larissa Araujo Duarte3, Andreza Salvio Lemos3, Helena Alessi4, Shaila Amorim Vieira2, Gabriel D'Angelo Lacerda2, LILIA ALVES MARIA ALVES MARIA4, Soniza Leon Alves3 and Cristiane Kayser4, 1Universidade Federal de São Paulo, SAO PAULO, Sao Paulo, Brazil, 2Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, Sao Paulo, Brazil, 3Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, 4Universidade Federal de São Paulo, São Paulo, Sao Paulo, Brazil

    Background/Purpose: Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) are common and frequently represent a diagnostic challenge due to its heterogeneous manifestations. Neurofilament light chain (NfL)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology